<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">Lung cancer</z:e> is the leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> worldwide, and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is its most common histological subtype </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical and molecular evidence indicates that <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disease, which has important implications for treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Here we performed genome-scale DNA methylation profiling using the Illumina Infinium HumanMethylation27 platform on 59 matched <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp>/non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lung pairs, with genome-scale verification on an independent set of tissues </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 766 genes showing altered DNA methylation between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lung </plain></SENT>
<SENT sid="4" pm="."><plain>By integrating DNA methylation and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression data, we identified 164 hypermethylated genes showing concurrent down-regulation, and 57 hypomethylated genes showing increased expression </plain></SENT>
<SENT sid="5" pm="."><plain>Integrated pathways analysis indicates that these genes are involved in cell differentiation, epithelial to mesenchymal transition, <z:mp ids='MP_0011356'>RAS</z:mp> and WNT signaling pathways, and cell cycle regulation, among others </plain></SENT>
<SENT sid="6" pm="."><plain>Comparison of DNA methylation profiles between <z:mp ids='MP_0002027'>lung adenocarcinomas</z:mp> of current and never-smokers showed modest differences, identifying only LGALS4 as significantly hypermethylated and down-regulated in smokers </plain></SENT>
<SENT sid="7" pm="."><plain>LGALS4, encoding a <z:chebi fb="0" ids="24163">galactoside</z:chebi>-binding protein involved in cell-cell and cell-matrix interactions, was recently shown to be a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Unsupervised analysis of the DNA methylation data identified two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> subgroups, one of which showed increased DNA methylation and was significantly associated with KRAS mutation and to a lesser extent, with smoking </plain></SENT>
<SENT sid="9" pm="."><plain>Our analysis lays the groundwork for further molecular studies of <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> by identifying novel epigenetically deregulated genes potentially involved in <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> development/progression, and by describing an epigenetic subgroup of <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> associated with characteristic molecular alterations </plain></SENT>
</text></document>